There could be millions of people walking around every day unaware their immune systems are engaged in an invisible battle with a chronic infection that’s putting them at risk for serious health issues. Despite the introduction of a vaccine more than 20 years ago, chronic hepatitis B (CHB) is still very much a public threat, and many live with the virus undiagnosed. The question is: why?
\nAccording to the World Health Organisation(WHO), nearly 300 million people globally are living with chronic hepatitis B. However, the Polaris Observatory estimates that only about 10% of these people are diagnosed, and only 5% receive treatment.
\nCHB is mostly acquired in early life, as the virus is often transmitted from mother to child during childbirth or infancy. The virus then hides in the liver to avoid the immune system and replicates itself, emitting more virus into the body and releasing particles known as hepatitis B surface antigen (HBsAg) to distract and exhaust the immune cells that are trying to eliminate it.
\nFor scientists researching CHB, there is an added complication. It is a heterogenous condition, which means the onset and progression of the virus are different in different types of patients according to their genetic make-up and immune systems. As a result, not all infections present in the same way, and not all people newly infected with the virus experience symptoms immediately. But there are many innovators and medical professionals working to develop new treatments for CHB. Melanie Paff, VP and Medicine Development Leader at GSK, is one of them.
\n“Underdiagnosis is particularly worrying to healthcare providers because hepatitis B infections can lead to serious consequences over time,” says Melanie.
\n“Infection from HBV is considered ‘chronic’ when the body’s immune system is unable to fight off the virus, so it persists in the blood and liver – putting people at high risk of complications such as cirrhosis and liver cancer, which may lead to death.”
\nAccording to data from CDA shared by the World Hepatitis Alliance, individuals infected with CHB have a similar or significantly higher risk of developing cancer as someone who smokes one pack of cigarettes per day.
\nAt the moment, there are limited options for those living with hepatitis B, with no one-size-fits-all solutions. And while there are vaccines that help prevent viral infection, immunisation can’t help the millions of people already infected – many of whom are children, and who have to live with the virus and its consequences their whole lives.
\nAs well as experiencing the physical symptoms of CHB, a study about the impact of stigma of people living with CHB has shown people living with the virus face additional burdens that impact their wellbeing – fear, anxiety, social withdrawal and even financial loss.
\nA lack of public understanding about hepatitis B and unfounded fears about the way it is transmitted can lead to stigma and discrimination. Unwarranted concerns that, for example, the infection can be spread by skin-to-skin contact, can cause patients to feel socially isolated. This ultimately creates further barriers to diagnosis, as those at risk may feel reluctant to seek medical help.
\nJacki, who lives with CHB in the US, describes the anxiety he feels sharing his diagnosis with others.
\n“Most people do not want to share that they are infected with hepatitis B, they feel that they are stigmatised and they need to isolate themselves and not tell anyone that they have the virus,” he says.
\n“At work I started thinking, should I tell my co-workers? Should I let them know? At some point I did kind of tell my colleagues and I don’t know if they all knew at that time or not, but I started to hear back from them, ‘Oh, you have Hep B? Then you shouldn’t eat with me.’”
","useGreyBackground":false,"fullWidth":false},{"type":"image","image":{"src":"/media/salnlga5/gsk2305_patient-still_jacki-01_crop.jpg?width=1320&height=660&format=webp&quality=100&v=1dba2eb9d982610","alt":"A patient, Jacki, headshot","darkModeSrc":"/media/salnlga5/gsk2305_patient-still_jacki-01_crop.jpg?width=1320&height=660&format=webp&quality=50&v=1dba2eb9d982610"},"link":null,"isFullPageWidth":false,"disableRoundedCorners":false,"expandableToAnOverlay":false,"portraitCrop":false,"cropTo75Width":false,"noCrop":false,"caption":"Jacki lives with Chronic Hep B in the US","title":null,"ariaHidden":false,"ariaFlipCard":"Flip card {title}","ariaImageButton":null},{"type":"rich-text","text":"People living with CHB often internalise stigma as well, meaning they can anticipate social rejection or negative stereotyping, in effect stigmatising themselves.
\nThe study about the impact of stigma of people living with CHB also revealed that some people also experience structural and institutional stigma, with one in five believing they may be denied healthcare, and up to 30% stating they may experience workplace discrimination.
\nNatalia, who lives with CHB in Germany, describes the worry that a diagnosis brings, and the importance of sharing information.
\n“I was thinking, ‘Have I endangered my daughters?’ I was really worried. This is when the disease started really affecting me. It can have an immense impact on people’s lives.
\n“Advocacy to other people with hepatitis B is of paramount importance. We make an effort to inform communities about different diseases. With COVID I do understand that it was a different type of virus, but everyone knew what they were dealing with and was bombarded with information.
\n“I’m really worried about hepatitis B and the impact it will have on my life.”
\nJane Dong, Clinical Research Physician at GSK, explains how this can be changed.
\n“The stigma associated with the hepatitis B virus impacts infection diagnosis, because the fear of being marked out as infected can deter people from coming forward for testing,” she says.
\n“We need to reduce the stigma associated with this disease through education and increase the global awareness of CHB to prevent the negative effects it can cause in the long term.
\n“We know that vaccination is an important step in preventing many types of infection. However, for those who already have the hepatitis B infection, to get ahead of the virus we must focus on early diagnosis, monitoring and treatment to reduce the risk for future liver-related complications.”
\nWith more than half of people with hepatitis B undiagnosed or unaware of their infection, increasing both knowledge and access to screening is crucial.
\nGetting more people to screenings would increase the number of people diagnosed with CHB. This could mean more people come forward for medical advice, and potentially for treatments that could prevent long-term damage.
\nThe U.S. Centers for Disease Control and Prevention (CDC) recently issued new recommendations for screening and testing for hepatitis B, stating all adults should be screened for HBV infection at least once in their lifetime. People who are not vaccinated for hepatitis B—but are at increased risk of HBV infection— should receive periodic testing.
","useGreyBackground":false,"fullWidth":false},{"type":"related-read-content","title":"Read related","relatedPage":{"title":"‘300 million people with chronic hepatitis B are waiting to re-start their lives. This is my story of hope.’","image":{"src":"/media/asfeht5a/maureen_maren_1200x628.png?format=webp&v=1dba2eb9eefede0","alt":"Two women with their arms around each other looking out at water","darkModeSrc":"/media/asfeht5a/maureen_maren_1200x628.png?format=webp&quality=50&v=1dba2eb9eefede0"},"link":{"text":"hepatitis b patient quote story functional cure","href":"/en-gb/behind-the-science-magazine/hepatitis-b-patient-quote-story-functional-cure/","openInNewWindowText":null},"label":"Behind the Science magazine","authorName":"Maureen Kamischke"}},{"type":"rich-text","text":"Similar momentum is building in countries like Australia, where experts are calling for all Australian adults to be screened for hepatitis B.
\n“We’re still learning a lot about the pathology of liver diseases, but also about the ways that they affect people and about the way that that affects their interaction with healthcare professionals,” says Stuart Kendrick, VP, Global Medical Affairs in Hepatology and Early Assets, and hepatologist.
\n“Sometimes we need to understand a lot more about how the patient feels about a diagnosis of hepatitis B or another liver disease and how that influences their attitude to treatment because that will really help us to advise them and help them to making a right treatment decision for them.”
\nSo how do healthcare professionals treat those patients who do get diagnosed?
\nAntiviral therapies can help to control the infection. However, lifelong medications are inconvenient and must be administered daily.
\nThe ultimate treatment goal for someone living with CHB is “functional cure”. This is achieved when the virus is undetectable in the blood and the liver, the infection is fully controlled by the immune system without daily medication, and liver function has returned to normal.
\nWhile a functional cure does not eliminate HBV from the body, it helps protect people from the worst outcomes of CHB, like cirrhosis and liver cancer, which may lead to death. It also reduces the risk of transmitting CHB to others.
\nEach day scientists – including those at GSK – discover more about liver diseases, and how we can utilise new technology like AI to match individual patients to the best treatments.
\n“Whilst the ultimate aim is to eliminate CHB entirely, the immediate goal is to make progress towards potential new treatments that can improve functional cure rates among those living with CHB,” Kendrick concludes.
\n“And, along the way, it’s also crucial to work towards improving education and awareness of CHB to remove barriers to diagnosis and tackle the stigma associated with this condition.”
","useGreyBackground":false,"fullWidth":false},{"type":"varied-signpost-grid","title":"","layoutPattern":4,"pages":[{"title":"‘Teenagers may feel invincible – but we’re at risk’: What you need to know about meningitis as post-COVID cases continue to rebound","content":"Around 1 in 10 of us carry the most common cause of bacterial meningitis in our nose and throats. Here are the signs to look out for","image":{"src":"/media/k1gjjpmi/katepatientimage1.jpg?width=427&height=533&format=webp&quality=100&v=1dc087318adb210","alt":"Patient Kate holds up a photograph showing the rash she suffered from on her legs when she had IMD","darkModeSrc":"/media/k1gjjpmi/katepatientimage1.jpg?width=427&height=533&format=webp&quality=50&v=1dc087318adb210"},"link":{"text":"meningitis cases rebound risks symptoms","href":"/en-gb/behind-the-science-magazine/meningitis-cases-rebound-risks-symptoms/","openInNewWindowText":null}},{"title":"Back to school immunity: vaccination catch-ups are needed to stop the escalation of preventable diseases in children","content":"Medical experts say now is the time to catch up on essential immunisation programs to ensure young people and communities are protected","image":{"src":"/media/fncla5pw/shutterstock_1738679645.jpg?width=427&height=533&format=webp&quality=100&v=1dba2eb9e86a4c0","alt":"School children walking outside","darkModeSrc":"/media/fncla5pw/shutterstock_1738679645.jpg?width=427&height=533&format=webp&quality=50&v=1dba2eb9e86a4c0"},"link":{"text":"child immunity gap vaccination catch up","href":"/en-gb/behind-the-science-magazine/child-immunity-gap-vaccination-catch-up/","openInNewWindowText":null}}],"hidePageDescription":true,"useGreyBackground":false}]},"id":6362,"docCheckLogout":null,"pageType":"magazinePage","languageCode":"en-GB","theme":"light","breadcrumb":{"ariaLabel":"Breadcrumb","links":[{"text":"Home","href":"/en-gb/","openInNewWindowText":null},{"text":"Behind the Science magazine","href":"/en-gb/behind-the-science-magazine/","openInNewWindowText":null},{"text":"Millions of people living with chronic hepatitis B are unaware they have the virus. So why aren’t they getting diagnosed?","href":"/en-gb/behind-the-science-magazine/chronic-hepatitis-b-stigma-discrimination-diagnosis/","openInNewWindowText":null}]},"pageName":"Millions of people living with chronic hepatitis B are unaware they have the virus. So why aren’t they getting diagnosed?","topNav":{"homeLink":{"text":"GSK Homepage","href":"/en-gb/","openInNewWindowText":null},"topBar":{"currentLocation":{"isGlobal":true,"text":"Global"},"languageSelector":{"currentLanguage":null,"currentLanguageMobile":null,"selectableLanguages":[]},"darkModeSwitch":{"text":"Dark mode","tooltipText":"Switch to dark mode to head towards a more sustainable world together. More info
"},"globalSiteLink":null,"locationSelector":{"text":"Change location","href":"/en-gb/locations/","openInNewWindowText":null},"healthCareLink":{"text":"Healthcare professionals","href":"https://www.gskpro.com","target":"_blank","openInNewWindowText":"Opens in a new window"},"contactUs":{"text":"Contact us","href":"/en-gb/contact-us/","openInNewWindowText":null},"search":"Search","backToMain":"Back to main","menu":"Menu","closeMenu":"Close menu","animationsToggleModel":{"enable":true,"activeText":"Pause video","inactiveText":"Play video"}},"nodes":[{"tooltip":null,"hasBorderRight":true,"title":"Behind the Science magazine","url":"/en-gb/behind-the-science-magazine/","nodes":[],"isActive":true,"promos":[]},{"tooltip":null,"hasBorderRight":false,"title":"Company","url":"/en-gb/company/","nodes":[{"title":"Purpose, strategy and culture","url":"/en-gb/company/purpose-strategy-and-culture/","nodes":[],"isActive":false},{"title":"Outstanding people","url":"/en-gb/company/outstanding-people/","nodes":[{"title":"Great place to work","url":"/en-gb/company/outstanding-people/great-place-to-work/","nodes":[],"isActive":false},{"title":"Meet our veterans","url":"/en-gb/company/outstanding-people/meet-our-veterans/","nodes":[],"isActive":false},{"title":"Working together","url":"/en-gb/company/outstanding-people/working-together/","nodes":[],"isActive":false},{"title":"My GSK story","url":"/en-gb/company/outstanding-people/my-gsk-story/","nodes":[],"isActive":false},{"title":"Innovating together","url":"/en-gb/company/outstanding-people/innovating-together/","nodes":[],"isActive":false}],"isActive":false},{"title":"GSK at a glance","url":"/en-gb/company/gsk-at-a-glance/","nodes":[],"isActive":false},{"title":"History and heritage","url":"/en-gb/company/history-and-heritage/","nodes":[],"isActive":false},{"title":"Board of Directors and Executive Committee","url":"/en-gb/company/board-of-directors-and-leadership-team/","nodes":[],"isActive":false},{"title":"Board information","url":"/en-gb/company/board-information/","nodes":[],"isActive":false},{"title":"Governance","url":"/en-gb/company/governance/","nodes":[{"title":"Committees","url":"/en-gb/company/governance/committees/","nodes":[],"isActive":false},{"title":"Shareholders","url":"/en-gb/company/governance/shareholders/","nodes":[],"isActive":false},{"title":"Sarbanes-Oxley Act 2002","url":"/en-gb/company/governance/sarbanes-oxley-act-2002/","nodes":[],"isActive":false},{"title":"Compliance","url":"/en-gb/company/governance/compliance/","nodes":[],"isActive":false}],"isActive":false},{"title":"Policy positions","url":"/en-gb/company/policy-positions/","nodes":[],"isActive":false},{"title":"Codes, standards and reports","url":"/en-gb/company/codes-standards-and-reports/","nodes":[],"isActive":false}],"isActive":false,"promos":[{"text":"Our purpose, strategy and culture","image":{"src":"/media/vvwddvsg/gsk_tech_human_image_6k.jpg?rxy=0.56833333333333336,0.30177514792899407&width=329&height=185&format=webp&quality=100&v=1dba2ec0bc1e680","alt":"GSK Tech Human Image","darkModeSrc":"/media/vvwddvsg/gsk_tech_human_image_6k.jpg?rxy=0.56833333333333336,0.30177514792899407&width=329&height=185&format=webp&quality=50&v=1dba2ec0bc1e680"},"link":{"text":"FEATURED SECTION","href":"/en-gb/company/purpose-strategy-and-culture/","openInNewWindowText":null}},{"text":"Outstanding people","image":{"src":"/media/kgwp0dc5/sddefault-2.jpg?rxy=0.425,0.51807228915662651&width=329&height=185&format=webp&quality=100&v=1dba2eba773f3d0","alt":"Angeles sitting on a sofa in a pink shirt","darkModeSrc":"/media/kgwp0dc5/sddefault-2.jpg?rxy=0.425,0.51807228915662651&width=329&height=185&format=webp&quality=50&v=1dba2eba773f3d0"},"link":{"text":"FEATURED SECTION","href":"/en-gb/company/outstanding-people/","openInNewWindowText":null}}]},{"tooltip":null,"hasBorderRight":false,"title":"Innovation","url":"/en-gb/innovation/","nodes":[{"title":"Our leading scientists","url":"/en-gb/innovation/our-leading-scientists/","nodes":[{"title":"Dr Tony Wood","url":"/en-gb/innovation/our-leading-scientists/tony-wood/","nodes":[],"isActive":false},{"title":"Dr Sabine Luik","url":"/en-gb/innovation/our-leading-scientists/sabine-luik/","nodes":[],"isActive":false},{"title":"Dr Hesham Ahmed Abdullah","url":"/en-gb/innovation/our-leading-scientists/hesham-abdullah/","nodes":[],"isActive":false},{"title":"Dr Kaivan Khavandi","url":"/en-gb/innovation/our-leading-scientists/kaivan-khavandi/","nodes":[],"isActive":false},{"title":"Dr Christopher Austin","url":"/en-gb/innovation/our-leading-scientists/dr-christopher-austin/","nodes":[],"isActive":false}],"isActive":false},{"title":"Research and development approach","url":"/en-gb/innovation/research-and-development-approach/","nodes":[],"isActive":false},{"title":"Pipeline","url":"/en-gb/innovation/pipeline/","nodes":[],"isActive":false},{"title":"Therapeutic areas","url":"/en-gb/innovation/therapeutic-areas/","nodes":[{"title":"Respiratory, immunology and inflammation","url":"/en-gb/innovation/therapeutic-areas/respiratory-immunology-and-inflammation/","nodes":[],"isActive":false},{"title":"Oncology","url":"/en-gb/innovation/therapeutic-areas/oncology/","nodes":[],"isActive":false},{"title":"HIV","url":"/en-gb/innovation/therapeutic-areas/hiv/","nodes":[],"isActive":false},{"title":"Infectious diseases","url":"/en-gb/innovation/therapeutic-areas/infectious-diseases/","nodes":[],"isActive":false}],"isActive":false},{"title":"Tech","url":"/en-gb/innovation/technologies/","nodes":[],"isActive":false},{"title":"Clinical trials at GSK","url":"/en-gb/innovation/trials/","nodes":[{"title":"Provision of unapproved medicines for unmet medical needs","url":"/en-gb/innovation/trials/provision-of-unlicensed-medicines-for-unmet-medical-needs/","nodes":[],"isActive":false},{"title":"Data transparency","url":"/en-gb/innovation/trials/data-transparency/","nodes":[],"isActive":false},{"title":"Representative clinical studies","url":"/en-gb/innovation/trials/representative-clinical-studies/","nodes":[],"isActive":false}],"isActive":false},{"title":"Partnering with GSK","url":"/en-gb/innovation/partnerships/","nodes":[{"title":"Supported studies","url":"/en-gb/innovation/partnerships/supported-studies/","nodes":[],"isActive":false}],"isActive":false},{"title":"R&D locations","url":"/en-gb/innovation/rd-locations/","nodes":[],"isActive":false}],"isActive":false,"promos":[{"text":"Behind the science magazine","image":{"src":"/media/ukvllwft/vaccine-manufacturing-production-line-2.jpg?width=329&height=185&format=webp&quality=100&v=1dba2ebb585f130","alt":"Scientist works in a futurist vaccine laboratory for GSK","darkModeSrc":"/media/ukvllwft/vaccine-manufacturing-production-line-2.jpg?width=329&height=185&format=webp&quality=50&v=1dba2ebb585f130"},"link":{"text":"SPOTLIGHT ON","href":"/en-gb/behind-the-science-magazine/","openInNewWindowText":null}},{"text":"Our leading scientists","image":{"src":"/media/45khexa4/tony-16x9.jpg?rxy=0.5733215608441357,0.39891812701082546&width=329&height=185&format=webp&quality=100&v=1dc651e856734f0","alt":"Tony Wood","darkModeSrc":"/media/45khexa4/tony-16x9.jpg?rxy=0.5733215608441357,0.39891812701082546&width=329&height=185&format=webp&quality=50&v=1dc651e856734f0"},"link":{"text":"Featured section","href":"/en-gb/innovation/our-leading-scientists/","openInNewWindowText":null}}]},{"tooltip":null,"hasBorderRight":false,"title":"Products","url":"/en-gb/products/","nodes":[{"title":"Product areas","url":"/en-gb/products/our-product-areas/","nodes":[],"isActive":false},{"title":"Products A-Z","url":"/en-gb/products/products-a-z/","nodes":[],"isActive":false}],"isActive":false,"promos":[{"text":"Innovation","image":{"src":"/media/jxkd3fld/web03-header-stvg_2_2022_port_5_hess_nav.jpg?width=329&height=185&format=webp&quality=100&v=1dba2ebbe22d650","alt":"Lab technician leaning against wall","darkModeSrc":"/media/jxkd3fld/web03-header-stvg_2_2022_port_5_hess_nav.jpg?width=329&height=185&format=webp&quality=50&v=1dba2ebbe22d650"},"link":{"text":"SPOTLIGHT ON","href":"/en-gb/innovation/","openInNewWindowText":null}},{"text":"GSKPro for healthcare professionals ","image":{"src":"/media/xpibjmpq/navthumb_stvg_03_2022_port_32_eagle_orange-1.jpg?width=329&height=185&format=webp&quality=100&v=1dba2ebbe35c210","alt":"Two scientists on orange background","darkModeSrc":"/media/xpibjmpq/navthumb_stvg_03_2022_port_32_eagle_orange-1.jpg?width=329&height=185&format=webp&quality=50&v=1dba2ebbe35c210"},"link":{"text":"FEATURED WEBSITE","href":"https://gskpro.com","target":"_blank","openInNewWindowText":"Opens in a new window"}}]},{"tooltip":null,"hasBorderRight":true,"title":"Responsibility","url":"/en-gb/responsibility/","nodes":[{"title":"Access","url":"/en-gb/responsibility/access/","nodes":[],"isActive":false},{"title":"Global health and health security","url":"/en-gb/responsibility/global-health-and-health-security/","nodes":[{"title":"Global health","url":"/en-gb/responsibility/global-health-and-health-security/global-health/","nodes":[],"isActive":false},{"title":"Health security","url":"/en-gb/responsibility/global-health-and-health-security/health-security/","nodes":[],"isActive":false},{"title":"Using our science for global health","url":"/en-gb/responsibility/global-health-and-health-security/using-our-science-for-global-health/","nodes":[],"isActive":false},{"title":"Improving access to healthcare","url":"/en-gb/responsibility/global-health-and-health-security/improving-access-to-healthcare/","nodes":[],"isActive":false},{"title":"Africa Open Lab","url":"/en-gb/responsibility/global-health-and-health-security/africa-open-lab/","nodes":[],"isActive":false}],"isActive":false},{"title":"Environment","url":"/en-gb/responsibility/environment/","nodes":[{"title":"Climate","url":"/en-gb/responsibility/environment/climate/","nodes":[],"isActive":false},{"title":"Freshwater","url":"/en-gb/responsibility/environment/freshwater/","nodes":[],"isActive":false},{"title":"Land","url":"/en-gb/responsibility/environment/land/","nodes":[],"isActive":false},{"title":"Oceans","url":"/en-gb/responsibility/environment/oceans/","nodes":[],"isActive":false},{"title":"Materials and waste","url":"/en-gb/responsibility/environment/materials-and-waste/","nodes":[],"isActive":false},{"title":"Health system sustainability","url":"/en-gb/responsibility/environment/health-system-sustainability/","nodes":[],"isActive":false}],"isActive":false},{"title":"Inclusion","url":"/en-gb/responsibility/inclusion/","nodes":[],"isActive":false},{"title":"Ethical standards","url":"/en-gb/responsibility/ethical-standards/","nodes":[{"title":"Working with third parties","url":"/en-gb/responsibility/ethical-standards/working-with-third-parties/","nodes":[],"isActive":false},{"title":"Public policy and patient advocacy","url":"/en-gb/responsibility/ethical-standards/public-policy-and-patient-advocacy/","nodes":[],"isActive":false},{"title":"Human rights","url":"/en-gb/responsibility/ethical-standards/human-rights/","nodes":[],"isActive":false},{"title":"Use of animals","url":"/en-gb/responsibility/ethical-standards/use-of-animals/","nodes":[],"isActive":false},{"title":"Engaging with healthcare professionals","url":"/en-gb/responsibility/ethical-standards/engaging-with-healthcare-professionals/","nodes":[],"isActive":false}],"isActive":false},{"title":"Product governance","url":"/en-gb/responsibility/product-governance/","nodes":[],"isActive":false},{"title":"Grants and donations","url":"/en-gb/responsibility/grants-and-donations/","nodes":[],"isActive":false},{"title":"Charitable investments ","url":"/en-gb/responsibility/charitable-investments/","nodes":[],"isActive":false},{"title":"Responsibility reports","url":"/en-gb/responsibility/responsibility-reports/","nodes":[{"title":"Reports archive","url":"/en-gb/responsibility/responsibility-reports/responsibility-reports-archive/","nodes":[],"isActive":false}],"isActive":false}],"isActive":false,"promos":[{"text":"Inclusion","image":{"src":"/media/2u2dowa1/web16-header-stvg_2_2022_port_13_hess_nav.jpg?width=329&height=185&format=webp&quality=100&v=1dba2ebc1b88030","alt":"Lab technician smiling","darkModeSrc":"/media/2u2dowa1/web16-header-stvg_2_2022_port_13_hess_nav.jpg?width=329&height=185&format=webp&quality=50&v=1dba2ebc1b88030"},"link":{"text":"FEATURED SECTION","href":"/en-gb/responsibility/inclusion/","openInNewWindowText":null}},{"text":"Our policy positions","image":{"src":"/media/110ltmz5/gsk_texture_fluid_03_a_cmyk_web-size_nav.jpg?width=329&height=185&format=webp&quality=100&v=1dba2ebbe9b61b0","alt":"GSK orange texture","darkModeSrc":"/media/110ltmz5/gsk_texture_fluid_03_a_cmyk_web-size_nav.jpg?width=329&height=185&format=webp&quality=50&v=1dba2ebbe9b61b0"},"link":{"text":"SPOTLIGHT ON","href":"/en-gb/company/policy-positions/","openInNewWindowText":null}}]},{"tooltip":null,"hasBorderRight":false,"title":"Investors","url":"/en-gb/investors/","nodes":[{"title":"Why invest in GSK?","url":"/en-gb/investors/why-invest-in-gsk/","nodes":[],"isActive":false},{"title":"Quarterly results","url":"/en-gb/investors/quarterly-results/","nodes":[],"isActive":false},{"title":"Financial reports","url":"/en-gb/investors/financial-reports/","nodes":[{"title":"Annual Report 2025","url":"/en-gb/investors/financial-reports/annual-report-2025/","nodes":[],"isActive":false},{"title":"Corporate reports archive","url":"/en-gb/investors/financial-reports/corporate-reports-archive/","nodes":[],"isActive":false}],"isActive":false},{"title":"Responsible business","url":"/en-gb/investors/responsible-business/","nodes":[],"isActive":false},{"title":"Speeches and presentations","url":"/en-gb/investors/speeches-and-presentations/","nodes":[],"isActive":false},{"title":"Science publications","url":"/en-gb/investors/science-publications/","nodes":[],"isActive":false},{"title":"Events calendar","url":"/en-gb/investors/events-calendar/","nodes":[],"isActive":false},{"title":"Dividend and share price","url":"/en-gb/investors/dividend-and-share-price/","nodes":[{"title":"GSK share price","url":"/en-gb/investors/dividend-and-share-price/gsk-share-price/","nodes":[],"isActive":false},{"title":"Share price calculators (GBp/USD)","url":"/en-gb/investors/dividend-and-share-price/share-price-calculators-gbpusd/","nodes":[],"isActive":false},{"title":"Dividend calculators (GBp/USD)","url":"/en-gb/investors/dividend-and-share-price/dividend-calculators-gbpusd/","nodes":[],"isActive":false},{"title":"Dividend calendar","url":"/en-gb/investors/dividend-and-share-price/dividend-calendar/","nodes":[],"isActive":false}],"isActive":false},{"title":"Analyst consensus","url":"/en-gb/investors/analyst-consensus/","nodes":[],"isActive":false},{"title":"Stock exchange announcements","url":"/en-gb/investors/stock-exchange-announcements/","nodes":[{"title":"London (RNS)","url":"/en-gb/investors/stock-exchange-announcements/london-rns/","nodes":[],"isActive":false},{"title":"London (RNS) inside information","url":"/en-gb/investors/stock-exchange-announcements/london-rns-inside-information/","nodes":[],"isActive":false},{"title":"New York (SEC)","url":"/en-gb/investors/stock-exchange-announcements/new-york-sec/","nodes":[],"isActive":false},{"title":"Sign up for announcements","url":"/en-gb/investors/stock-exchange-announcements/sign-up-for-announcements/","nodes":[],"isActive":false}],"isActive":false},{"title":"Shareholder information","url":"/en-gb/investors/shareholder-information/","nodes":[{"title":"Manage your shares","url":"/en-gb/investors/shareholder-information/manage-your-shares/","nodes":[],"isActive":false},{"title":"Annual General Meeting","url":"/en-gb/investors/shareholder-information/annual-general-meeting/","nodes":[],"isActive":false},{"title":"General Meeting","url":"/en-gb/investors/shareholder-information/general-meeting/","nodes":[],"isActive":false},{"title":"Annual Governance Meeting","url":"/en-gb/investors/shareholder-information/annual-governance-meeting/","nodes":[],"isActive":false},{"title":"Corporate sponsored nominee service","url":"/en-gb/investors/shareholder-information/corporate-sponsored-nominee-service/","nodes":[],"isActive":false},{"title":"Our ADR programme","url":"/en-gb/investors/shareholder-information/adr-programme/","nodes":[],"isActive":false},{"title":"Asset reunification - Georgeson ","url":"/en-gb/investors/shareholder-information/asset-reunification-georgeson/","nodes":[],"isActive":false},{"title":"Share scam alert","url":"/en-gb/investors/shareholder-information/share-scam-alert/","nodes":[],"isActive":false},{"title":"Privacy notice for ordinary shareholders","url":"/en-gb/investors/shareholder-information/privacy-notice-for-ordinary-shareholders/","nodes":[],"isActive":false},{"title":"FAQs","url":"/en-gb/investors/shareholder-information/shareholder-faqs/","nodes":[],"isActive":false}],"isActive":false},{"title":"Corporate actions","url":"/en-gb/investors/corporate-actions/","nodes":[{"title":"Consumer Healthcare Demerger","url":"/en-gb/investors/corporate-actions/consumer-healthcare-demerger/","nodes":[],"isActive":false},{"title":"Consumer Healthcare Joint Venture","url":"/en-gb/investors/corporate-actions/consumer-healthcare-joint-venture/","nodes":[],"isActive":false},{"title":"Agreement to acquire TESARO","url":"/en-gb/investors/corporate-actions/agreement-to-acquire-tesaro/","nodes":[],"isActive":false}],"isActive":false},{"title":"Debt investors","url":"/en-gb/investors/debt-investors/","nodes":[],"isActive":false},{"title":"Investor contacts","url":"/en-gb/investors/investor-contacts/","nodes":[],"isActive":false}],"isActive":false,"promos":[{"text":"Press releases","image":{"src":"/media/hb1dfygw/ware_3_2022_prodassmb_28_hess_nav.jpeg?width=329&height=185&format=webp&quality=100&v=1dba2ebc6f12bb0","alt":"Lab machinery","darkModeSrc":"/media/hb1dfygw/ware_3_2022_prodassmb_28_hess_nav.jpeg?width=329&height=185&format=webp&quality=50&v=1dba2ebc6f12bb0"},"link":{"text":"SPOTLIGHT ON","href":"/en-gb/media/press-releases/","openInNewWindowText":null}},{"text":"Our pipeline","image":{"src":"/media/2kyan0vw/ware_3_2022_prodqc_14_hess.jpeg?width=329&height=185&format=webp&quality=100&v=1dba2ebc701f490","alt":"Case of vials","darkModeSrc":"/media/2kyan0vw/ware_3_2022_prodqc_14_hess.jpeg?width=329&height=185&format=webp&quality=50&v=1dba2ebc701f490"},"link":{"text":"SPOTLIGHT ON","href":"/en-gb/innovation/pipeline/","openInNewWindowText":null}}]},{"tooltip":null,"hasBorderRight":false,"title":"Media","url":"/en-gb/media/","nodes":[{"title":"Press releases","url":"/en-gb/media/press-releases/","nodes":[],"isActive":false},{"title":"Media contacts","url":"/en-gb/media/media-contacts/","nodes":[],"isActive":false},{"title":"Media library","url":"/en-gb/media/media-library/","nodes":[],"isActive":false},{"title":"Zantac litigation","url":"/en-gb/media/zantac-litigation/","nodes":[],"isActive":false},{"title":"GSK's position on Flovent","url":"/en-gb/media/gsks-position-on-flovent/","nodes":[],"isActive":false},{"title":"Our social media","url":"/en-gb/media/social-media/","nodes":[],"isActive":false},{"title":"Podcasts","url":"/en-gb/media/podcasts/","nodes":[],"isActive":false},{"title":"RSS feeds","url":"/en-gb/media/rss-feeds/","nodes":[],"isActive":false}],"isActive":false,"promos":[{"text":"Behind the science magazine","image":{"src":"/media/ukvllwft/vaccine-manufacturing-production-line-2.jpg?width=329&height=185&format=webp&quality=100&v=1dba2ebb585f130","alt":"Scientist works in a futurist vaccine laboratory for GSK","darkModeSrc":"/media/ukvllwft/vaccine-manufacturing-production-line-2.jpg?width=329&height=185&format=webp&quality=50&v=1dba2ebb585f130"},"link":{"text":"Spotlight on","href":"/en-gb/behind-the-science-magazine/","openInNewWindowText":null}}]},{"tooltip":null,"hasBorderRight":false,"title":"Careers","url":"/en-gb/careers/","nodes":[{"title":"Search jobs","url":"/en-gb/careers/search-jobs/","nodes":[],"isActive":false},{"title":"Featured careers","url":"/en-gb/careers/featured-careers/","nodes":[{"title":"A career in data","url":"/en-gb/careers/featured-careers/a-career-in-data/","nodes":[],"isActive":false}],"isActive":false},{"title":"Life at GSK","url":"/en-gb/careers/life-at-gsk/","nodes":[],"isActive":false},{"title":"Experienced professionals","url":"/en-gb/careers/experienced-professionals/","nodes":[{"title":"Business operations","url":"/en-gb/careers/experienced-professionals/business-operations/","nodes":[],"isActive":false},{"title":"Engineering at GSK ","url":"/en-gb/careers/experienced-professionals/engineering/","nodes":[],"isActive":false},{"title":"Global supply chain","url":"/en-gb/careers/experienced-professionals/global-supply-chain/","nodes":[],"isActive":false},{"title":"Sales and marketing","url":"/en-gb/careers/experienced-professionals/sales-and-marketing/","nodes":[],"isActive":false},{"title":"Research and development","url":"/en-gb/careers/experienced-professionals/research-and-development/","nodes":[{"title":"Chemical Manufacturing and Controls (CMC), Medicine Development and Supply (MDS)","url":"/en-gb/careers/experienced-professionals/research-and-development/chemical-manufacturing-and-controls-cmc-medicine-development-and-supply-mds/","nodes":[],"isActive":false},{"title":"Genomic sciences","url":"/en-gb/careers/experienced-professionals/research-and-development/genomic-sciences/","nodes":[],"isActive":false}],"isActive":false},{"title":"Technology","url":"/en-gb/careers/experienced-professionals/technology/","nodes":[],"isActive":false}],"isActive":false},{"title":"Early careers","url":"/en-gb/careers/early-careers/","nodes":[{"title":"Application process","url":"/en-gb/careers/early-careers/application-process/","nodes":[],"isActive":false},{"title":"Apprentice programmes","url":"/en-gb/careers/early-careers/apprentice-programmes/","nodes":[],"isActive":false},{"title":"Internships and placements","url":"/en-gb/careers/early-careers/internships-and-placements/","nodes":[],"isActive":false},{"title":"Graduate programme","url":"/en-gb/careers/early-careers/graduate-programme/","nodes":[{"title":"Business operations","url":"/en-gb/careers/early-careers/graduate-programme/business-operations/","nodes":[],"isActive":false},{"title":"Engineering","url":"/en-gb/careers/early-careers/graduate-programme/engineering/","nodes":[],"isActive":false},{"title":"Manufacturing & supply","url":"/en-gb/careers/early-careers/graduate-programme/manufacturing-supply/","nodes":[],"isActive":false},{"title":"Commercial ","url":"/en-gb/careers/early-careers/graduate-programme/commercial/","nodes":[],"isActive":false},{"title":"Research & development","url":"/en-gb/careers/early-careers/graduate-programme/research-development/","nodes":[],"isActive":false},{"title":"Digital & tech","url":"/en-gb/careers/early-careers/graduate-programme/digital-tech/","nodes":[],"isActive":false},{"title":"Manufacturing sciences & technology","url":"/en-gb/careers/early-careers/graduate-programme/manufacturing-sciences-technology/","nodes":[],"isActive":false}],"isActive":false},{"title":"Post graduate opportunities","url":"/en-gb/careers/early-careers/post-graduate-opportunities/","nodes":[],"isActive":false},{"title":"Frequently asked questions","url":"/en-gb/careers/early-careers/frequently-asked-questions/","nodes":[],"isActive":false}],"isActive":false},{"title":"Veterans","url":"/en-gb/careers/veterans/","nodes":[],"isActive":false},{"title":"Our global and regional hubs","url":"/en-gb/careers/our-global-and-regional-hubs/","nodes":[],"isActive":false},{"title":"How we hire","url":"/en-gb/careers/how-we-hire/","nodes":[{"title":"Fraudulent internet recruitment activities","url":"/en-gb/careers/how-we-hire/fraudulent-internet-recruitment-activities/","nodes":[],"isActive":false},{"title":"Frequently asked questions","url":"/en-gb/careers/how-we-hire/frequently-asked-questions/","nodes":[],"isActive":false}],"isActive":false}],"isActive":false,"promos":[{"text":"Outstanding people","image":{"src":"/media/kgwp0dc5/sddefault-2.jpg?rxy=0.425,0.51807228915662651&width=329&height=185&format=webp&quality=100&v=1dba2eba773f3d0","alt":"Angeles sitting on a sofa in a pink shirt","darkModeSrc":"/media/kgwp0dc5/sddefault-2.jpg?rxy=0.425,0.51807228915662651&width=329&height=185&format=webp&quality=50&v=1dba2eba773f3d0"},"link":{"text":"Spotlight on","href":"/en-gb/company/outstanding-people/","openInNewWindowText":null}},{"text":"Inclusion","image":{"src":"/media/2u2dowa1/web16-header-stvg_2_2022_port_13_hess_nav.jpg?width=329&height=185&format=webp&quality=100&v=1dba2ebc1b88030","alt":"Lab technician smiling","darkModeSrc":"/media/2u2dowa1/web16-header-stvg_2_2022_port_13_hess_nav.jpg?width=329&height=185&format=webp&quality=50&v=1dba2ebc1b88030"},"link":{"text":"Spotlight on","href":"/en-gb/responsibility/inclusion/","openInNewWindowText":null}}]}],"skipToContent":"Skip to content","skipToSearch":"Skip to search","typeaheadSearch":{"apiEndpoint":"api/search/typeahead?siteContainerId=1703","searchFieldPlaceholderText":"Enter a search term...","searchPage":"/en-gb/search/","ariaLabel":"Submit form"},"ariaLabel":"Global navigation"},"footer":{"logo":null,"copyrightText":"This is our global website, intended for visitors seeking information on GSK's worldwide business. Our market sites can be reached by visiting our location selector.
\n\n
© 2001-2026 GSK plc. All rights reserved. Trade marks are owned by or licensed to the GSK group of companies.
\nGSK plc. Registered in England and Wales No. 3888792.
\nRegistered office: 79 New Oxford Street, London. United Kingdom. WC1A 1DG
","modernSlaveryStatement":{"name":"Modern Slavery Act Statement 2025","url":"/media/5ladhmeu/modern-slavery-act-statement-2025.pdf","fileExtension":"PDF","fileSize":"187.7KB","type":"file","target":"_blank","openInNewWindowText":"Opens in a new window"},"sections":{"socialMedia":{"columnTitle":"Follow us on:","socialMediaItems":[{"globalLink":{"text":null,"href":"http://www.linkedin.com/company/glaxosmithkline","target":"_blank","openInNewWindowText":"Opens in a new window"},"localLink":null,"ariaLabel":"Visit GSK on Linkedin","customIcon":null,"showPopupMenu":false,"type":"LinkedIn"},{"globalLink":{"text":null,"href":"http://twitter.com/GSK","target":"_blank","openInNewWindowText":"Opens in a new window"},"localLink":null,"ariaLabel":"Visit GSK X page","customIcon":null,"showPopupMenu":false,"type":"X"},{"globalLink":{"text":null,"href":"https://bsky.app/profile/gsk.bsky.social/","target":"_blank","openInNewWindowText":"Opens in a new window"},"localLink":null,"ariaLabel":"","customIcon":null,"showPopupMenu":false,"type":"Bluesky"},{"globalLink":{"text":null,"href":"https://www.instagram.com/gsk/","target":"_blank","openInNewWindowText":"Opens in a new window"},"localLink":null,"ariaLabel":"Visit GSK Instagram","customIcon":null,"showPopupMenu":false,"type":"Instagram"},{"globalLink":{"text":null,"href":"https://www.facebook.com/GSK","target":"_blank","openInNewWindowText":"Opens in a new window"},"localLink":null,"ariaLabel":"Visit GSK Facebook page","customIcon":null,"showPopupMenu":false,"type":"Facebook"},{"globalLink":{"text":null,"href":"http://www.youtube.com/GSK","target":"_blank","openInNewWindowText":"Opens in a new window"},"localLink":null,"ariaLabel":"Visit GSK YouTube Channel","customIcon":null,"showPopupMenu":false,"type":"Youtube"},{"globalLink":{"text":null,"href":"/en-gb/media/rss-feeds/","openInNewWindowText":null},"localLink":null,"ariaLabel":"Visit GSK RSS feeds","customIcon":null,"showPopupMenu":false,"type":"Rss"}]},"columns":[{"columnTitle":"GSK websites","links":[{"text":"Locations selector","href":"/en-gb/locations/","openInNewWindowText":null},{"text":"Social media directory","href":"/en-gb/media/social-media/","openInNewWindowText":null},{"text":"GSKPro for healthcare professionals","href":"https://www.gskpro.com","target":"_blank","openInNewWindowText":"Opens in a new window"},{"text":"GSK study register","href":"https://www.gsk-studyregister.com/en/","target":"_blank","openInNewWindowText":"Opens in a new window"},{"text":"Supplier website","href":"https://supplier.gsk.com","target":"_blank","openInNewWindowText":"Opens in a new window"},{"text":"ViiV Healthcare","href":"https://viivhealthcare.com/","target":"_blank","openInNewWindowText":"Opens in a new window"}]},{"columnTitle":"Quick links","links":[{"text":"Behind the Science magazine","href":"/en-gb/behind-the-science-magazine/","openInNewWindowText":null},{"text":"Company","href":"/en-gb/company/","openInNewWindowText":null},{"text":"Innovation","href":"/en-gb/innovation/","openInNewWindowText":null},{"text":"Products","href":"/en-gb/products/","openInNewWindowText":null},{"text":"Responsibility","href":"/en-gb/responsibility/","openInNewWindowText":null},{"text":"Investors","href":"/en-gb/investors/","openInNewWindowText":null},{"text":"Media","href":"/en-gb/media/","openInNewWindowText":null},{"text":"Careers","href":"/en-gb/careers/","openInNewWindowText":null}]},{"columnTitle":"Get in touch","links":[{"text":"Contact us","href":"/en-gb/contact-us/","openInNewWindowText":null},{"text":"Partnerships","href":"/en-gb/innovation/partnerships/","openInNewWindowText":null},{"text":"Report a possible side effect","href":"/en-gb/contact-us/report-a-possible-side-effect/","openInNewWindowText":null},{"text":"GSK Speak up","href":"https://www.gsk.com/speakup","target":"_blank","openInNewWindowText":"Opens in a new window"}]}]},"bottomLinks":[{"text":"Accessibility","href":"/en-gb/accessibility/","openInNewWindowText":null},{"text":"Digital sustainability","href":"/en-gb/digital-sustainability/","openInNewWindowText":null},{"text":"Terms of use","href":"/en-gb/terms-of-use/","openInNewWindowText":null},{"text":"Cookie policy","href":"/en-gb/cookie-policy/","openInNewWindowText":null},{"text":"Privacy notice","href":"https://privacy.gsk.com/en-gb/privacy-notice/general","target":"_blank","openInNewWindowText":"Opens in a new window"},{"text":"Sitemap","href":"/en-gb/sitemap/","openInNewWindowText":null}],"continueToLink":null,"legalApprovalText":""},"sharing":{"description":"Under-diagnosis of chronic hepatitis B is worrying healthcare professionals because it can lead to serious consequences over time.","og":[{"property":"og:title","content":"Millions of people living with chronic hepatitis B are unaware they have the virus. So why aren’t they getting diagnosed?"},{"property":"og:description","content":"Under-diagnosis of chronic hepatitis B is worrying healthcare professionals because it can lead to serious consequences over time."},{"property":"og:image","content":"https://www.gsk.com/media/pbjllxvw/natalia-still_crop.jpg?width=600&format=webp&quality=100&v=1dba2eb9d88e3d0"},{"property":"og:url","content":"https://www.gsk.com/en-gb/behind-the-science-magazine/chronic-hepatitis-b-stigma-discrimination-diagnosis/"}],"twitter":[{"name":"twitter:card","content":"summary_large_image"},{"name":"twitter:site","content":"@gsk"},{"name":"twitter:title","content":"Millions of people living with chronic hepatitis B are unaware they have the virus. So why aren’t they getting diagnosed?"},{"name":"twitter:description","content":"Under-diagnosis of chronic hepatitis B is worrying healthcare professionals because it can lead to serious consequences over time."},{"name":"twitter:image","content":"https://www.gsk.com/media/pbjllxvw/natalia-still_crop.jpg?width=600&format=webp&quality=100&v=1dba2eb9d88e3d0"},{"name":"twitter:url","content":"https://www.gsk.com/en-gb/behind-the-science-magazine/chronic-hepatitis-b-stigma-discrimination-diagnosis"}]},"stickyShare":{"href":"https://www.gsk.com/en-gb/behind-the-science-magazine/chronic-hepatitis-b-stigma-discrimination-diagnosis/","pageTitle":"Millions of people living with chronic hepatitis B are unaware they have the virus. So why aren’t they getting diagnosed?","shareText":"Share","newTabLinkText":"Opens in a new window","shareOnTwitterText":"Share on Twitter","shareOnLinkedInText":"Share on LinkedIn","shareOnFacebookText":"Share on Facebook"},"exitSitePreferences":{"popupEnabled":false,"title":"","texts":"","continueText":"Continue","cancelText":"Cancel","exclusionUrls":[]},"settings":{"optionalStylesheetLink":null,"themeColorHexCode":null,"headerLogoLightTheme":null,"headerLogoDarkTheme":null,"footerLogo":{"src":"https://www.gsk.com/media/0jwou3xu/gsk-logo.png?width=104&format=webp&quality=100&v=1dbf4b05a4e6470","alt":"Gsk Logo","darkModeSrc":"https://www.gsk.com/media/0jwou3xu/gsk-logo.png?width=104&format=webp&quality=50&v=1dbf4b05a4e6470"},"scripts":[{"pageLocation":"Top","text":" \n"}],"globalWebsiteLink":null,"googleMapsApiKey":"AIzaSyA2QMg4Ww6djPKb7b9BraQn4kgJmDaLblg","textToSpeechApiKey":"70ab0a79-1d92-4286-86d2-abdd71cc785c","bingVerificationCode":"","googleAnalytics":"","siteTitle":" | GSK"},"pageSettings":{"disableBackToTopButton":false,"backToTopButtonText":"Back to top","robotsNoFollow":false,"robotsNoIndex":false,"canonicalUrl":"https://www.gsk.com/en-gb/behind-the-science-magazine/chronic-hepatitis-b-stigma-discrimination-diagnosis/"},"tealiumSettings":{"enabled":false,"data":""},"entryPopup":null,"protectedPage":false,"schema":{"jsonLdSchemas":["{\"@context\":\"https://schema.org\",\"@type\":\"Article\",\"description\":\"Under-diagnosis of chronic hepatitis B is worrying healthcare professionals because it can lead to serious consequences over time.\",\"image\":{\"@type\":\"ImageObject\",\"image\":\"https://www.gsk.com/media/pbjllxvw/natalia-still_crop.jpg\"},\"mainEntityOfPage\":\"https://www.gsk.com/en-gb/behind-the-science-magazine/chronic-hepatitis-b-stigma-discrimination-diagnosis/\",\"url\":\"https://www.gsk.com/en-gb/behind-the-science-magazine/chronic-hepatitis-b-stigma-discrimination-diagnosis/\",\"datePublished\":\"2023-11-06T00:00:00+00:00\",\"headline\":\"Millions of people living with chronic hepatitis B are unaware they have the virus. So why aren\\u2019t they getting diagnosed?\",\"keywords\":\"Specialty,Immunology\",\"articleBody\":\"There could be millions of people walking around every day unaware their immune systems are engaged in an invisible battle with a chronic infection that\\u2019s putting them at risk for serious health issues. Despite the introduction of a vaccine more than 20 years ago, chronic hepatitis B (CHB) is still very much a public threat, and many live with the virus undiagnosed. The question is: why? According to the World Health Organisation(WHO), nearly 300 million people globally are living with chronic hepatitis B. However, the Polaris Observatory estimates that only about 10% of these people are diagnosed, and only 5% receive treatment. \\u00A0CHB is mostly acquired in early life, as the virus is often transmitted from mother to child during childbirth or infancy. The virus then hides in the liver to avoid the immune system and replicates itself, emitting more virus into the body and releasing particles known as hepatitis B surface antigen (HBsAg) to distract and exhaust the immune cells that are trying to eliminate it.For scientists researching CHB, there is an added complication. It is a heterogenous condition, which means the onset and progression of the virus are different in different types of patients according to their genetic make-up and immune systems. As a result, not all infections present in the same way, and not all people newly infected with the virus experience symptoms immediately. But there are many innovators and medical professionals working to develop new treatments for CHB. Melanie Paff, VP and Medicine Development Leader at GSK, is one of them.\\u201CUnderdiagnosis is particularly worrying to healthcare providers because hepatitis B infections can lead to serious consequences over time,\\u201D says Melanie.\\u201CInfection from HBV is considered \\u2018chronic\\u2019 when the body\\u2019s immune system is unable to fight off the virus, so it persists in the blood and liver \\u2013 putting people at high risk of complications such as cirrhosis and liver cancer, which may lead to death.\\u201DAccording to data from CDA shared by the World Hepatitis Alliance, individuals infected with CHB have a similar or significantly higher risk of developing cancer as someone who smokes one pack of cigarettes per day.At the moment, there are limited options for those living with hepatitis B, with no one-size-fits-all solutions. And while there are vaccines that help prevent viral infection, immunisation can\\u2019t help the millions of people already infected \\u2013 many of whom are children, and who have to live with the virus and its consequences their whole lives.Carrying the burdenAs well as experiencing the physical symptoms of CHB, a study about the impact of stigma of people living with CHB has shown people living with the virus face additional burdens that impact their wellbeing \\u2013 fear, anxiety, social withdrawal and even financial loss.A lack of public understanding about hepatitis B and unfounded fears about the way it is transmitted can lead to stigma and discrimination. Unwarranted concerns that, for example, the infection can be spread by skin-to-skin contact, can cause patients to feel socially isolated. This ultimately creates further barriers to diagnosis, as those at risk may feel reluctant to seek medical help.Jacki, who lives with CHB in the US, describes the anxiety he feels sharing his diagnosis with others.\\u201CMost people do not want to share that they are infected with hepatitis B, they feel that they are stigmatised and they need to isolate themselves and not tell anyone that they have the virus,\\u201D he says.\\u201CAt work I started thinking, should I tell my co-workers? Should I let them know? At some point I did kind of tell my colleagues and I don\\u2019t know if they all knew at that time or not, but I started to hear back from them, \\u2018Oh, you have Hep B? Then you shouldn\\u2019t eat with me.\\u2019\\u201DPeople living with CHB often internalise stigma as well, meaning they can anticipate social rejection or negative stereotyping, in effect stigmatising themselves.The study about the impact of stigma of people living with CHB also revealed that some people also experience structural and institutional stigma, with one in five believing they may be denied healthcare, and up to 30% stating they may experience workplace discrimination.Natalia, who lives with CHB in Germany, describes the worry that a diagnosis brings, and the importance of sharing information.\\u201CI was thinking, \\u2018Have I endangered my daughters?\\u2019 I was really worried. This is when the disease started really affecting me. It can have an immense impact on people\\u2019s lives.\\u201CAdvocacy to other people with hepatitis B is of paramount importance. We make an effort to inform communities about different diseases. With COVID I do understand that it was a different type of virus, but everyone knew what they were dealing with and was bombarded with information.\\u201CI\\u2019m really worried about hepatitis B and the impact it will have on my life.\\u201DJane Dong, Clinical Research Physician at GSK, explains how this can be changed.\\u201CThe stigma associated with the hepatitis B virus impacts infection diagnosis, because the fear of being marked out as infected can deter people from coming forward for testing,\\u201D she says.\\u201CWe need to reduce the stigma associated with this disease through education and increase the global awareness of CHB to prevent the negative effects it can cause in the long term.\\u201CWe know that vaccination is an important step in preventing many types of infection. However, for those who already have the hepatitis B infection, to get ahead of the virus we must focus on early diagnosis, monitoring and treatment to reduce the risk for future liver-related complications.\\u201DGetting aheadWith more than half of people with hepatitis B undiagnosed or unaware of their infection, increasing both knowledge and access to screening is crucial.Getting more people to screenings would increase the number of people diagnosed with CHB. This could mean more people come forward for medical advice, and potentially for treatments that could prevent long-term damage.The U.S. Centers for Disease Control and Prevention (CDC) recently issued new recommendations for screening and testing for hepatitis B, stating all adults should be screened for HBV infection at least once in their lifetime. People who are not vaccinated for hepatitis B\\u2014but are at increased risk of HBV infection\\u2014 should receive periodic testing.Similar momentum is building in countries like Australia, where experts are calling for all Australian adults to be screened for hepatitis B.\\u201CWe\\u2019re still learning a lot about the pathology of liver diseases, but also about the ways that they affect people and about the way that that affects their interaction with healthcare professionals,\\u201D says Stuart Kendrick, VP, Global Medical Affairs in Hepatology and Early Assets, and hepatologist.\\u201CSometimes we need to understand a lot more about how the patient feels about a diagnosis of hepatitis B or another liver disease and how that influences their attitude to treatment because that will really help us to advise them and help them to making a right treatment decision for them.\\u201DThe ultimate goalSo how do healthcare professionals treat those patients who do get diagnosed?Antiviral therapies can help to control the infection. However, lifelong medications are inconvenient and must be administered daily.The ultimate treatment goal for someone living with CHB is \\u201Cfunctional cure\\u201D. This is achieved when the virus is undetectable in the blood and the liver, the infection is fully controlled by the immune system without daily medication, and liver function has returned to normal.While a functional cure does not eliminate HBV from the body, it helps protect people from the worst outcomes of CHB, like cirrhosis and liver cancer, which may lead to death. It also reduces the risk of transmitting CHB to others.Each day scientists \\u2013 including those at GSK \\u2013 discover more about liver diseases, and how we can utilise new technology like AI to match individual patients to the best treatments.\\u201CWhilst the ultimate aim is to eliminate CHB entirely, the immediate goal is to make progress towards potential new treatments that can improve functional cure rates among those living with CHB,\\u201D Kendrick concludes.\\u201CAnd, along the way, it\\u2019s also crucial to work towards improving education and awareness of CHB to remove barriers to diagnosis and tackle the stigma associated with this condition.\\u201D\",\"articleSection\":\"Behind the Science magazine - Feature\"}"]}}